News und Analysen
![Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline
Pfizer Inc. (NYSE: PFE) announced today that its board of directors declared a 38-cent per share first-quarter 2020 dividend on the company’s common stock, payable March 6, 2020 to holders of the
![Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the
![FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment
![Humana Announces New Care Coordination Services for Members With Kidney Disease](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Humana Announces New Care Coordination Services for Members With Kidney Disease
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its care management portfolio by teaming up with two specialized care management companies to offer personalized
![Waters Corporation Announces 2025 Sustainability Goals](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Waters Corporation Announces 2025 Sustainability Goals
Waters Corporation (NYSE:WAT) today announced its 2025 sustainability goals and simultaneously announced a commitment to report its sustainability progress annually. These goals were developed
![ArQule: +100% nach Milliarden-Übernahme](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
ArQule: +100% nach Milliarden-Übernahme
Das amerikanische Pharmakonglomerat Merck & Co. (WKN: A0YD8Q) akquiriert den Biotechforscher ArQule (WKN: 903396) für 20 US-Dollar je Aktie. Merck legt für die Übernahme 2,7 Milliarden US-Dollar in
![Agilent Ranked Among Top Four Best Workplaces in Greater China and Receives Certification as a Best Workplace for Women in Greater China](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Agilent Ranked Among Top Four Best Workplaces in Greater China and Receives Certification as a Best Workplace for Women in Greater China
Agilent Technologies, Inc. (NYSE: A) today announced it has been selected as one of the top four “Best Workplaces™ in Greater China” by the Great Place to Work® (GPTW) Institute. The company has
![Vertex Pharmaceuticals: Starke Aktie aus starkem Sektor](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Vertex Pharmaceuticals: Starke Aktie aus starkem Sektor
Relativ unbemerkt von der breiten Öffentlichkeit konnte der NASDAQ Biotechnology Index (NBI) zuletzt in der Spitze um fast +25% zulegen. Einer der Treiber dieser Kursrally war dabei, mal wieder, das
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical
![Mountain View Medical Group Signs New In-Network Agreement with Humana](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Mountain View Medical Group Signs New In-Network Agreement with Humana
Humana Inc. (NYSE: HUM), a leading health and well-being company, has reached an agreement that provides its members in-network access to Mountain View Medical Group in Colorado Springs.
This
![Agilent Receives Multiple Life Science Industry Awards for Innovation](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Receives Multiple Life Science Industry Awards for Innovation
Agilent Technologies Inc. (NYSE: A) announced today that it has received two Life Science Industry Awards (LSIA) for ‘Most Innovative New Products in 2019’ from BioInformatics Inc. Since 2002, the
![Agilent Technologies Reports Fourth-Quarter and Fiscal Year 2019 Financial Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Technologies Reports Fourth-Quarter and Fiscal Year 2019 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.37 billion for the fourth quarter ended Oct. 31, 2019, up 6% year over year (core(1) growth of 4%).
On a GAAP basis
![Humana Honored for Hispanic Inclusion Efforts](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Humana Honored for Hispanic Inclusion Efforts
Humana Inc. (NYSE: HUM) has again scored well in the HACR Corporate Inclusion Index, an annual survey by the Hispanic Association on Corporate Responsibility that measures companies’ business
![Humana and Epione Health Team Up to Offer a Patient-Centered Experience for Humana Medicare Advantage Members in Oklahoma](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Humana and Epione Health Team Up to Offer a Patient-Centered Experience for Humana Medicare Advantage Members in Oklahoma
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced it has collaborated with Epione Health of Oklahoma, LLC on a value-based agreement designed to offer a coordinated
![SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS®
![Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC)](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC)
Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labeled for use in HNSCC in the European Union.
The assay is CE-IVD–marked as an aid in
![Humana Improves Health and Reduces $3.5 Billion in Health Care Costs through Medicare Advantage Value-Based Care Programs](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Improves Health and Reduces $3.5 Billion in Health Care Costs through Medicare Advantage Value-Based Care Programs
Helping people living with multiple chronic conditions achieve their optimal whole-person health has been a strategic initiative for Humana Inc. (NYSE: HUM). Today, Humana announced that the
![Agilent Announces Applications Open for LabCentral Golden Ticket](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Announces Applications Open for LabCentral Golden Ticket
Agilent Technologies Inc. (NYSE: A) has announced that the nomination process to submit proposals to receive an Agilent-sponsored LabCentral Golden Ticket is open for interested life sciences and
![Agilent Technologies Increases Cash Dividend to 18 Cents Per Share](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Agilent Technologies Increases Cash Dividend to 18 Cents Per Share
Agilent Technologies, Inc. (NYSE: A) today announced that its board of directors has increased the company’s quarterly dividend to 18 cents per share of common stock, reflecting a 10 percent
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Evercore ISI HealthCONx
![Humana and agilon health Expand Relationship, Announce Value-Based Agreements with Physician Groups](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Humana and agilon health Expand Relationship, Announce Value-Based Agreements with Physician Groups
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, announced today that it has signed value-based care agreements with agilon health, which helps physicians and
![Humana and Hawaii Senior Medical Group Announce Agreement Expanding Value-Based Care for Humana Medicare Advantage Members in Hawaii](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Humana and Hawaii Senior Medical Group Announce Agreement Expanding Value-Based Care for Humana Medicare Advantage Members in Hawaii
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced it has collaborated with Hawaii Senior Medical Group on a value-based agreement designed to offer a coordinated
![Humana Pharmacy Wins Specialty Pharmacy Patient Choice Award, Two Years in a Row](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Humana Pharmacy Wins Specialty Pharmacy Patient Choice Award, Two Years in a Row
The specialty pharmacy team of Humana Pharmacy, the mail-delivery pharmacy service of Humana Inc. (NYSE: HUM), received the Specialty Pharmacy Patient Choice Award in the PBM/Payer Specialty
![Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence
Agilent Technologies Inc. (NYSE: A) today announced a new generation of ICP-OES systems for laboratories serving the environmental, food, energy, chemicals, and materials markets.
The new Agilent
![FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the